These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30606472)

  • 21. Current concepts in the treatment of familial hypercholesterolaemia.
    Packard CJ; Shepherd J
    Curr Opin Lipidol; 1995 Feb; 6(1):57-61. PubMed ID: 7735717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
    Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
    Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation.
    Shirahama R; Ono T; Nagamatsu S; Sueta D; Takashio S; Chitose T; Fujisue K; Sakamoto K; Yamamoto E; Izumiya Y; Kaikita K; Hokimoto S; Hori M; Harada-Shiba M; Kajiwara I; Ogawa H; Tsujita K
    Intern Med; 2018; 57(24):3551-3557. PubMed ID: 30555118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Familial Hypercholesterolaemia Regression Study and its implications.
    Watts GF
    Lancet; 1995 Apr; 345(8953):807-8. PubMed ID: 7898224
    [No Abstract]   [Full Text] [Related]  

  • 26. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study.
    Stefanutti C; Mazza F; Mesce D; Morozzi C; Di Giacomo S; Vitale M; Pergolini M
    Atheroscler Suppl; 2017 Nov; 30():86-91. PubMed ID: 29096866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance.
    Kolovou G; Vasiliadis I; Gontoras N; Kolovou V; Hatzigeorgiou G
    Cardiovasc Ther; 2015 Apr; 33(2):71-8. PubMed ID: 25604780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Lipo- Phenotypic Screening Tool for Familial Hypercholesterolaemia.
    Kalra S; Kishor K; Sawhney J; Kumar K; Raza SA; Shrestha D; Aye TT; Chaudhary S; Shaikh K; Somasundaram N; Pathan F; Sahay R; Priya G
    J Pak Med Assoc; 2019 Jul; 69(7):1052-1054. PubMed ID: 31983747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF)].
    Ascaso JF; Mata P; Arbona C; Civeira F; Valdivielso P; Masana L
    Clin Investig Arterioscler; 2015; 27(2):80-96. PubMed ID: 25757840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homozygous familial hypercholesterolaemia: metabolic studies and treatment with LDL apheresis.
    Mol MJ; Stalenhoef AF
    Neth J Med; 1990 Jun; 36(5-6):279-87. PubMed ID: 2395495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.
    Watts GF; Gidding S; Wierzbicki AS; Toth PP; Alonso R; Brown WV; Bruckert E; Defesche J; Lin KK; Livingston M; Mata P; Parhofer KG; Raal FJ; Santos RD; Sijbrands EJ; Simpson WG; Sullivan DR; Susekov AV; Tomlinson B; Wiegman A; Yamashita S; Kastelein JJ;
    Eur J Prev Cardiol; 2015 Jul; 22(7):849-54. PubMed ID: 24776375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Small Change Can Make a Big Difference: A Lesson from Evolocumab.
    Mirzaee S; Thein PM; Wong D; Nasis A
    Heart Lung Circ; 2019 Mar; 28(3):e21-e22. PubMed ID: 29685715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homozygous familial hypercholesterolaemia.
    Macchiaiolo M; Gagliardi MG; Toscano A; Guccione P; Bartuli A
    Lancet; 2012 Apr; 379(9823):1330. PubMed ID: 22285056
    [No Abstract]   [Full Text] [Related]  

  • 37. [Familial hypercholesterolemia: recognition and prevention of cardiac complications at a young age].
    Trip MD; Lansberg PJ; de Jongh S; Kastelein JJ
    Ned Tijdschr Geneeskd; 2000 Jul; 144(30):1425-8. PubMed ID: 10932693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholesterol-lowering and coronary atherosclerosis: good news and bad news.
    Kreisberg RA
    Am J Med; 1996 Nov; 101(5):455-8. PubMed ID: 8948266
    [No Abstract]   [Full Text] [Related]  

  • 39. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 40. Homozygous familial hypercholesterolaemia and treatment by LDL apheresis.
    King RI; Scott RS; Florkowski CM; Laurie AD; Reid N; George PM
    N Z Med J; 2010 Jul; 123(1319):79-82. PubMed ID: 20717180
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.